SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1184ssb prt 4: As Indiplon has a very rapid clearance from the body, with a short hmopgcw-11/11/2003
1183ssb prt 3: UPDATE ON INDIPLON According to Neurocrine, to date, Indiplon hasmopgcw-11/11/2003
1182SSB prt 2: SG&A expense of $5 million for Q3 2003 was generally in-line wmopgcw-11/11/2003
1181ssb Report: NBIX: Third Quarter Earnings; Indiplon Remains on Track HOLD (2) Smopgcw-11/11/2003
1180SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (NasdaMiljenko Zuanic-11/10/2003
1179ITEM 1. LEGAL PROCEEDINGS [From the 10Q filed today]. The Salk Institute has nIcebrg-11/7/2003
1178Quarterly and 12m running figures. <pre> Quarterly Q3_03 Q2_03 Q1_03 Q4_Icebrg-11/4/2003
1177Pharmacopeia Forms New Research Collaboration With Neurocrine 2003-10-20 08:02 (mopgcw-10/20/2003
1176NBIX: Detailed Phase III Results for Indiplon MR mopgcw-9/25/2003
1175While LSO data are at borderline, TST and WASO data are solid (WASO at second weMiljenko Zuanic-9/24/2003
1174Neurocrine Reports Phase III Indiplon Results In Patients With Chronic Insomnia scaram(o)uche-9/24/2003
1173<i> Chronic use claims might open up for and even require a much more far-Biomaven-9/17/2003
1172>>Thoughts?>> They mentioned that in their Q2-report. My feeling isIcebrg-9/16/2003
1171Message 19311177 Thoughts? Cheers, Tucktuck-9/16/2003
1170I look at nbix as a late stage bio, mega deal with Pfizer, that now has $500M inrkrw-9/12/2003
1169Erik, I knew that was the generalized sense of "dilution" you were addquidditch-9/12/2003
1168>> No real dilution there.>> One of the problems with dilution is tIcebrg-9/12/2003
1167Ice, Agreed as to the equity infusion, but <The dilution is about 12 %. I canquidditch-9/12/2003
1166>>3.75 Million Shares priced at $53.00 per share.>> A good, straighIcebrg-9/12/2003
11653.75 Million Shares priced at $53.00 per share. Morgan Stanley and Merrill keokalani'nui-9/11/2003
1164Neurocrine Biosciences Announces Public Offering Of 3 Million Shares of Common Smopgcw-9/5/2003
1163Steinman's next generation "vaccines"....... Nature Biotechnologscaram(o)uche-8/10/2003
1162Neurocrine Biosciences Announces Initiation of Phase II Clinical Trial With NBI-Icebrg-7/28/2003
1161SSB Report: Neurocrine Biosciences (NBIX) NBIX: Indiplon Development Program Exmopgcw-7/28/2003
1160From today’s PFE CC: by: DewDiligence 07/25/03 12:03 pm Msg: 5667 of 5667 “Wekeokalani'nui-7/25/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News